What is HC Wainwright’s Forecast for ACHV FY2030 Earnings?

Achieve Life Sciences, Inc. (NASDAQ:ACHV) – HC Wainwright issued their FY2030 EPS estimates for shares of Achieve Life Sciences in a note issued to investors on Monday, January 26th. HC Wainwright analyst B. Folkes forecasts that the biopharmaceutical company will post earnings per share of $1.64 for the year. The consensus estimate for Achieve Life Sciences’ current full-year earnings is ($1.17) per share.

Achieve Life Sciences (NASDAQ:ACHV) last issued its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04).

Other equities analysts also recently issued reports about the company. Citizens Jmp started coverage on Achieve Life Sciences in a research report on Tuesday, November 25th. They set a “market outperform” rating and a $19.00 price objective for the company. Raymond James Financial restated a “strong-buy” rating on shares of Achieve Life Sciences in a research report on Monday, November 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Achieve Life Sciences in a research report on Monday, December 29th. Finally, Citigroup began coverage on shares of Achieve Life Sciences in a report on Tuesday, November 25th. They issued an “outperform” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Achieve Life Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $15.50.

Achieve Life Sciences Stock Down 9.1%

Shares of ACHV opened at $5.09 on Tuesday. The stock’s 50-day moving average price is $4.84 and its two-hundred day moving average price is $3.87. Achieve Life Sciences has a 12 month low of $1.84 and a 12 month high of $6.03. The company has a market capitalization of $270.94 million, a PE ratio of -3.69 and a beta of 1.71. The company has a current ratio of 5.14, a quick ratio of 5.14 and a debt-to-equity ratio of 0.26.

Institutional Trading of Achieve Life Sciences

Several institutional investors and hedge funds have recently made changes to their positions in ACHV. AQR Capital Management LLC bought a new stake in shares of Achieve Life Sciences in the first quarter valued at $32,000. Next Capital Management LLC purchased a new stake in shares of Achieve Life Sciences in the 3rd quarter valued at about $51,000. Sender Co & Partners Inc. purchased a new stake in Achieve Life Sciences in the second quarter valued at approximately $56,000. OneDigital Investment Advisors LLC bought a new stake in shares of Achieve Life Sciences during the 3rd quarter worth $63,000. Finally, Bank of America Corp DE increased its stake in Achieve Life Sciences by 39.9% in the second quarter. Bank of America Corp DE now owns 33,731 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 9,617 shares during the last quarter. Hedge funds and other institutional investors own 33.52% of the company’s stock.

About Achieve Life Sciences

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.